The efficacy and tolerability of Botanix Pharmaceuticals' (ASX:BOT) Sofdra topical gel was rated highly in a survey of US dermatologists conducted by Euroz Hartleys, and the dermatologists reported that Sofdra is their preferred first-line option for treatment of axillary hyperhidrosis, except where insurers require step edits, the investment firm said in a note on Wednesday.

The survey involved in-depth interviews with five dermatologists who treated several hundred hyperhidrosis patients with the topical gel across different practice settings and regions of the US.

Virtually all patients were able to secure treatment with Sofdra, including insurance coverage, out-of-pocket costs, and ease of obtaining the prescription. The dermatologists ranked access and safety as equally important, ahead of efficacy.

Four of five dermatologists we interviewed said Sofdra changed how they manage hyperhidrosis, shifting from being reactive to proactive. Four of five dermatologists also observed some seasonality in when patients seek treatment.

The investment firm maintained its buy recommendation on Botanix Pharmaceuticals and kept its AU$0.44 per share price target.